CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response (MPR) rates compared with chemotherapy alone in resectable EGFR-mutant ...

Osimertinib plus chemotherapy has been granted Priority Review for locally advanced or metastatic EGFR-mutated NSCLC.

Single-agent osimertinib and the combination demonstrated activity in tumors with MET overexpression, MET amplification, or both. The study population had a median follow-up of 8.2 months.

Osimertinib plus savolitinib demonstrated stronger efficacy than osimertinib alone in patients with de novo MET-aberrant, EGFR-mutant advanced NSCLC in the FLOWERS study.

Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related cardiac events than those treated with other EGFR tyrosine kinase inhibitors ...

Besides the new approval, AstraZeneca released preliminary results for LAURA evaluating osimertinib after chemoradiotherapy.

Osimertinib after surgery significantly improves survival in patients with resected EGFR -mutated non-small cell lung cancer (ASCO press release).

Fexofenadine was shown to overcome osimertinib resistance in non-small cell lung cancer by inhibiting Met in vitro and in vivo.

Fortunately, the receipt of adjuvant osimertinib was similar among the three treatment arms, but it will be difficult to assess the contribution of the preoperative osimertinib and postoperative ...

Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to osimertinib alone, according to research presented ...

Osimertinib plus chemotherapy showed a statistically significant improvement in progression-free survival (PFS) vs osimertinib alone in patients with epidermal growth factor receptor–mutated ...

Osimertinib, sold under the brand name Tagrisso, is available to patients with Stage 1B-3A lung cancer who have a certain genetic mutation and have had surgery to remove cancerous tumors.